Clinical trials driving consolidation in IMP distribution and logistics industry, says PCI

By Dan Stanton contact

- Last updated on GMT

Related tags: Supply chain, Pharmacology

PCI opens clinical trial material logistics hub in US
PCI opens clinical trial material logistics hub in US
Consolidation in the healthcare logistics industry is inevitable, says PCI as it opens a US storage and distribution facility for clinical trial materials.

The new facility located in Rockford, Illinois, opened its doors this month offering 97,000 sq ft of expansive storage for investigational supplies at controlled room temperature, as well as cold chain storage capacity at 2-8°C, -20°C, and -80°C.

The news signals the latest expansion by PCI, the healthcare packaging and logistics offshoot of Frazier Healthcare, following the acquisitions of distribution firm Biotec Services in September​ and Welsh contract development and manufacturing organisation (CDMO) Penn Pharma in July​, and – according to SVP of Global Clinical Services Bob Misher – boosts the firm’s full scale clinical-to-commercial pipeline of services.

“PCI continues to expand its service offering to become a full service drug development partner to pharmaceutical and biotechnology companies,”​ he told Outsourcing-Pharma.com.

“Part of that service offering is extensive expertise and capability around global logistics for clinical trials and has been an area of investment due to growth in this segment of the market.”

Misher also told us the logistics industry for healthcare is evolving, being led by the growth of services to support investigational medicinal product (IMPs). “The management of the clinical supply chain has become one of the most important factors of any clinical trial, especially with Cold Chain products,”​ he said, with correct management “critical”​ to the success of each individual trial.

“Global logistics is highly complex and does require scale. More and more we are supporting investigational studies being executed in the element of Cold Chain,”​ he continued, adding this rising demand requires capital investment to offer extensive capacity and capability.

Therefore, “further consolidation in the industry is inevitable as smaller organizations will have difficulty managing the expanding global supply chain and its requirements.”

Related news

Show more

Related products

show more

QPS: Global Custom-Built Research Services

QPS: Global Custom-Built Research Services

QPS | 16-Dec-2019 | Product Brochure

Performing complex studies in special populations with remarkable agility. Clinical research just got better with QPS’ Custom-Built Research Services....

Validating The Simoa Technology

Validating The Simoa Technology

Frontage Laboratories | 01-Oct-2019 | Technical / White Paper

Frontage is the first and only laboratory to validate Quanterix’ Simoa HD1 Analyzer for performing immunoassays. Most of the advanced instruments used...

Related suppliers

Follow us

Products

View more

Webinars